The additive suppression of TGF-β1 induced ECM synthesis in vitro provided more powerful evidence for rosiglitazone modulating TGF-β1 induced fibrogenesis and made it to be a promising anti-fibrosis therapeutic agent for ADPKD. This evidence concerns the gene TGFB1 and autosomal dominant polycystic kidney disease.